Search - tctmd.com

Displaying 1 - 20 of 34

Sort: Relevancy | Date

News Daily News

Andexanet Alfa Pulled From US Market

Todd Neale

December 22, 2025

News Daily News

Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC

Michael O'Riordan

June 25, 2025

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

L.A. McKeown

January 24, 2025

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

News Daily News

FDA: No Signs of Link Between GLP-1s and Suicidal Thoughts, Actions

Todd Neale

January 12, 2024

News Features

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

L.A. McKeown

May 12, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

News Daily News

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

Michael O'Riordan

December 30, 2022

News Daily News

Reduction in BP Drives Treatment Preference for Hypertensive Patients

Michael O'Riordan

December 20, 2022

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

News Opinion CV Team Dispatch

November 2022 News Roundup

L.A. McKeown

November 01, 2022

News Daily News

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

Michael O'Riordan

March 01, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

News Daily News

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

Shelley Wood

October 15, 2021

News Daily News

FDA Issues New Guidance on Sodium Targets for Food Industry

L.A. McKeown

October 14, 2021

News Daily News

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

Yael L. Maxwell

May 28, 2020

News Daily News

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

Shelley Wood

February 26, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Advertisement

Andexanet Alfa Pulled From US Market

Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC

January 2025 Dispatch for the CV Team

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

FDA: No Signs of Link Between GLP-1s and Suicidal Thoughts, Actions

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

Reduction in BP Drives Treatment Preference for Hypertensive Patients

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

November 2022 News Roundup

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

FDA Approves Empagliflozin for Treatment of HFpEF

British Medical Groups Express Concern About Inclisiran Rollout

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

FDA Issues New Guidance on Sodium Targets for Food Industry

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content